289 related articles for article (PubMed ID: 15761193)
21. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells.
Thum T; Fraccarollo D; Galuppo P; Tsikas D; Frantz S; Ertl G; Bauersachs J
Cardiovasc Res; 2006 Apr; 70(1):50-60. PubMed ID: 16480696
[TBL] [Abstract][Full Text] [Related]
23. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Suh JW; Choi DJ; Chang HJ; Cho YS; Youn TJ; Chae IH; Kim KI; Kim CH; Kim HS; Oh BH; Park YB
J Korean Med Sci; 2010 Jan; 25(1):16-23. PubMed ID: 20052342
[TBL] [Abstract][Full Text] [Related]
24. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.
van der Harst P; Groenewegen HC; Roks AJ; Buikema H; Zijlstra F; van Gilst WH; de Smet BJ
Coron Artery Dis; 2008 Feb; 19(1):47-53. PubMed ID: 18281816
[TBL] [Abstract][Full Text] [Related]
25. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.
Kim YS; Ahn Y; Hong MH; Kim KH; Park HW; Hong YJ; Kim JH; Kim W; Jeong MH; Cho JG; Park JC; Kang JC
J Cardiovasc Pharmacol; 2007 Jun; 49(6):376-83. PubMed ID: 17577102
[TBL] [Abstract][Full Text] [Related]
26. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects.
Sironi L; Gianazza E; Gelosa P; Guerrini U; Nobili E; Gianella A; Cremonesi B; Paoletti R; Tremoli E
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):598-603. PubMed ID: 15681303
[TBL] [Abstract][Full Text] [Related]
27. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
Coban E; Afacan B
Platelets; 2008 Mar; 19(2):111-4. PubMed ID: 17852772
[TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat.
Loch D; Chan V; Hoey A; Brown L
Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):262-70. PubMed ID: 19583711
[TBL] [Abstract][Full Text] [Related]
29. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
Ii M; Nishimura H; Kusano KF; Qin G; Yoon YS; Wecker A; Asahara T; Losordo DW
Circulation; 2005 Jul; 112(1):93-102. PubMed ID: 15983249
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin improves pulse wave reflection by restoring endothelial function.
Ott C; Schneider MP; Schlaich MP; Schmieder RE
Microvasc Res; 2012 Jul; 84(1):60-4. PubMed ID: 22484031
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin-regulated post-translational phosphoproteome in human umbilical vein endothelial cells.
Huang B; Wu CH; Li FA; Liang SS; Shieh YH; Wang LD
Kaohsiung J Med Sci; 2013 Jul; 29(7):347-52. PubMed ID: 23768697
[TBL] [Abstract][Full Text] [Related]
32. Participation of K+ channels in the endothelium-dependent and endothelium-independent components of the relaxant effect of rosuvastatin in rat aortic rings.
López J; Mendoza R; Cleva Villanueva G; Martínez G; Castillo EF; Castillo C
J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):207-13. PubMed ID: 18635753
[TBL] [Abstract][Full Text] [Related]
33. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
34. Rapid regulation of platelet activation in vivo by nitric oxide.
Schäfer A; Wiesmann F; Neubauer S; Eigenthaler M; Bauersachs J; Channon KM
Circulation; 2004 Apr; 109(15):1819-22. PubMed ID: 15066953
[TBL] [Abstract][Full Text] [Related]
35. Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
Huang D; Wang FB; Guo M; Li S; Yan ML; Yu T; Wei M; Li JB
Int J Mol Med; 2015 Mar; 35(3):829-38. PubMed ID: 25524396
[TBL] [Abstract][Full Text] [Related]
36. Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin.
Molins B; Peña E; Padro T; Casani L; Mendieta C; Badimon L
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1246-52. PubMed ID: 20360535
[TBL] [Abstract][Full Text] [Related]
37. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism.
Liuni A; Luca MC; Gori T; Parker JD
J Am Coll Cardiol; 2010 Mar; 55(10):1002-6. PubMed ID: 20202516
[TBL] [Abstract][Full Text] [Related]
38. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR
Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
40. Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization.
Kerem A; Yin J; Kaestle SM; Hoffmann J; Schoene AM; Singh B; Kuppe H; Borst MM; Kuebler WM
Circ Res; 2010 Apr; 106(6):1103-16. PubMed ID: 20167930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
